The future is biopharmaceutical
When we analyze the molecular structure of cannabinoids, the research shows there are many active compounds – each with a myriad of possible pharmaceutical applications. A number of these have already been isolated with the potential to develop therapies effective in pain management and cancer treatment, epilepsy and a variety of neural disorders. And that is only scratching the surface.

A different approach. Rooted in science to reach for the miraculous.
A different model for a new frontier.

We are Scientus Pharma – a next gen R&D biopharmaceutical company that is uniquely prepared to tap the revolutionary potential of this dynamic new medical industry.

Scientus is a vertically-integrated firm that is far more than the sum of its parts. We are a Licensed Dealer, under the Narcotics Control Regulations of Canada, with a focus on developing and commercializing pharmaceutical-grade cannabinoid derivative products. As one of a limited number of Licensed Dealers in Canada able to work with cannabinoids, Scientus has the ability to wholesale buy, process and sell cannabinoid derivatives, from and to Licensed Producers, as well as to export and import to international markets.

Science-driven at every step, our formula for success is systematic and direct: we seek to combine intellectual capital with proven entrepreneurial acumen. Our goal is to provide the environment, technology, and infrastructure to make the leap from research concept to market reality.

By introducing proprietary new delivery methods and fixed dosage forms, Scientus looks to make positive changes in this industry and to enable people to prescribe and receive the optimal benefits of this therapy.

Scientus Pharma is based in the Greater Toronto Area in Canada, with research operations located at our R&D facilities at the dynamic MaRS Discovery District. We also have a large commercial production facility east of the city which houses a complete testing laboratory as well as an extensive GMP focused production environment.
Getting ahead of the curve to develop cutting-edge cannabinoid-based pharmaceutical products.

With such a massive wave of interest in medical cannabinoids, it’s as if the Gold Rush has now turned Green. At Scientus Pharma, we have already uncovered areas of remarkable potential with a focus on practical applications. We are leveraging state-of-the-art research to lay the groundwork for a pipeline of cannabis-based products and therapies for market.

In the general marketplace, the dust is far from settled. Science tells us the endocannabinoid system is implicated in many diseases. And while cannabinoids appear to hold remarkable potential for medical applications and treatment, the scientific community has largely been challenged by the regulatory environment to study its biological, physiological and chemical properties.

It is extremely difficult to get the regulatory approval required for research. Scientus started down this journey in 2013 and has already put into place the regulatory approvals to permit it to study all these areas of focus. In particular, we have studied individual cannabinoids and their mixes and ratios. As a result, we are able to profile and study the absorption into the body and effects on different systems including the endocannabinoid system. Today, we have advanced our work to a stage where we are approaching the commercialization stage of developing new and safe therapeutic drugs.

Our current focus is to apply our expertise to solve the scientific challenges at the root of the endocannabinoid system. In this crucial respect, Scientus has a considerable headstart on the field.

**The Scientus Advantage**

On the strength of our patent-pending extraction and processing methods, Scientus possesses the technology to produce continuous, consistent batch profiles. This is a key criteria in formulating pharma-grade derivative products.

Our products can be dispensed in a multitude of dosage forms, all providing standard measured doses for the reliable and consistent delivery of therapeutic formulations. All things considered, we are remarkably well-positioned to both anticipate and then lead the fast-track from research to market.
Understanding the science is our key to unlocking the greater market opportunities.

Endocannabinoid: The Scientific Perspective

Science is not just the intellectual understanding of how the endocannabinoid system works, but also an appreciation of the human body. Endocannabinoids are in our body and are found throughout the body. In the brain, immune system, and numerous other cells.

Receptors are derived from the natural plant and comprise a collection of over 100 chemical-based molecular receptors targeting the body's fundamental needs. These receptors have been classified into three phytochemical classes, and are found throughout the body; in the brain, organs, connective tissues, glands, and immune cells.

The endocannabinoid system occurs throughout the body, and are more numerous than other types of receptors and are found throughout the body: in the brain, organs, connective tissues, glands, and immune cells.

There are two major classes of receptors, cannabinoid receptors. The pharmacological study of these receptors has been central to the development of new drugs for the treatment of many disease indications in which the endocannabinoid system is implicated.

Endocannabinoids are a collection of over 100 chemical-based molecular receptors targeting the body's fundamental needs. These receptors have been classified into three phytochemical classes, and are found throughout the body: in the brain, organs, connective tissues, glands, and immune cells.

In the meantime we have the plant itself, which there are challenges to chemically and biologically profile. Another approach is to harness the plant's complexity to provide a standardized, metered dosing forms. Scientus has solved both the chemical and biological quality control methods to qualify the resin as an API-like material, profiling phytochemicals and designing an extraction method for extraction and activation of API from natural plant materials. The result is this from a pharmaceutical manufacturing perspective, you must somehow bring the API, nor do they compensate for large batch-to-batch variability inherent in natural plant materials. Scientus has developed a proprietary method to address this issue and to establish a diversity of drug therapies and treatments.

Taking a Different Approach

There are many approaches developing natural cannabis-based systems. Vanishing the plant's complexity and understanding the properties of the API, nor do they compensate for large batch-to-batch variability inherent in natural plant materials. The result is this from a pharmaceutical manufacturing perspective, you must somehow bring the API, nor do they compensate for large batch-to-batch variability inherent in natural plant materials. Scientus has developed a proprietary method to address this issue and to establish a diversity of drug therapies and treatments.

Phytocannabinoids are derived from the natural plant and comprise a collection of over 100 chemical-based molecular receptors targeting the body's fundamental needs. These receptors have been classified into three phytochemical classes, and are found throughout the body: in the brain, organs, connective tissues, glands, and immune cells.

In general, existing extraction methods have resulted in some dramatic failures. Attempts to synthesize various phytocannabinoids have also met with limited success. There can also be huge variability in batches of the cannabis plant. For example, we know that a cannabinoid-terpenes and flavonoids, can be effective in treating the symptoms of neuropathic pain. We can also be confident that it is suitable for treatment of many disease indications such as chronic pain, multiple sclerosis, PTSD, and others.

The cannabis plant is highly complex with over 500 elements. From a pharmaceutical industry perspective, it is an amorphous, ever-changing and variable collection of elements. From a pharmaceutical manufacturing perspective, you must somehow bring the API, nor do they compensate for large batch-to-batch variability inherent in natural plant materials.

In numerous studies, cannabinoids have been proven to be relatively safe. In drug research terms, it is difficult to demonstrate a lethal dose. There are however several other research terms, it is difficult to demonstrate a lethal dose. There are however several other

Phytocannabinoids are derived from the natural plant and comprise a collection of over 100 chemical-based molecular receptors targeting the body's fundamental needs. These receptors have been classified into three phytochemical classes, and are found throughout the body: in the brain, organs, connective tissues, glands, and immune cells.

In general, existing extraction methods have resulted in some dramatic failures. Attempts to synthesize various phytocannabinoids have also met with limited success. There can also be huge variability in batches of the cannabis plant. For example, we know that a cannabinoid-terpenes and flavonoids, can be effective in treating the symptoms of neuropathic pain. We can also be confident that it is suitable for treatment of many disease indications such as chronic pain, multiple sclerosis, PTSD, and others.

The cannabis plant is highly complex with over 500 elements. From a pharmaceutical industry perspective, it is an amorphous, ever-changing and variable collection of elements. From a pharmaceutical manufacturing perspective, you must somehow bring the API, nor do they compensate for large batch-to-batch variability inherent in natural plant materials. Scientius is successfully pursuing this different approach to establish a diversity of drug therapies and treatments.
Leadership. A high powered team fusing boardroom savvy with scientific acumen.

Scientus is a brilliant hive of innovation bringing together leading minds in the Life Sciences community. We represent a fusion of scientific and corporate experience with the diverse knowledge necessary to generate a cutting-edge product management team.

Har Grover  
Executive Chairman  
Entrepreneur, investor, senior executive and strategist with over 30 years of experience in healthcare, life sciences and technology.

Trevor Folk  
President & CEO  
Operator and entrepreneur primarily focused on the operation of businesses in highly regulated sectors.

Ray Grover  
Chief Financial Officer  
Chartered accountant with significant experience in business advisory and development.

Phillip A. Hemans  
Chief Business Officer  
Chartered accountant, experienced executive and proven entrepreneur.

Scientific Advisors  
Lakshmi Kotra,  
B.Pharm. (Hons), PhD  
Co-Chair  
Director at the Center for Molecular Design and Proformulations at University Health Network (UHN), a Senior Scientist at UHN, and Associate Professor of Medicinal Chemistry at University of Toronto.

Hance Clarke, MD, PhD, FRCPC,  
Co-Chair  
Director of Pain Services and the Medical Director of the Pain Research Unit at the Toronto General Hospital.

Eleanor N. Fish, Ph.D.  
Canada Research Chair in Women’s Health & Immunobiology, Professor of Immunology at the University of Toronto and a Senior Scientist at UHN in Toronto.

Barry Greenberg, Ph.D.  
Director, Neuroscience Drug Discovery and Development at UHN in Toronto.

Atul Humar, M.Sc., M.D.  
Director of the UHN Multi-Organ Transplant Program, and the University of Toronto Transplant Institute.

Orlando Hung, B. Pharm., M.D.  
Anesthesiologist, and specialist in pain management at Queen Elizabeth II Health Sciences Center in Halifax, Nova Scotia, and professor of Pharmacology and Anesthesiology at Dalhousie University.

Donald F. Weaver, M.D., Ph.D.  
Senior Scientist and Director of Krembil Research Institute at UHN, and professor of Pharmacy, Chemistry and Medicine at University of Toronto.
Scientus Pharma unites research & development and full commercial production facilities into one integrated organization.

Our research operations are based at the MaRS Discovery District in Toronto, widely considered the preeminent life sciences hub in Canada and amongst the finest in the world. MaRS Innovation spearheads an optimal environment for start-up success by providing early-stage seed investing for science and tech companies looking to get to market faster.

We also have full access to multiple research facilities through our relationship with the University Health Network, the largest biomedical research institution in Canada and one of the biggest in the world. Chief amongst them is the Center for Molecular Design and Preformulations (CMDP), where Scientus conducts research utilizing $25M of sophisticated lab equipment. It should be noted that all the lab equipment is rented in a true pharma grade facility, enabling us to keep start-up costs relatively low.

Commercial Facility
Scientus also owns and operates a 45,000 sq ft commercial production facility, 45 minutes from downtown Toronto. This facility provides a flexible pharmaceutical platform in full compliance with Health Canada’s quality and regulatory requirements. It also houses a fully equipped analytical and biological testing laboratory that allows Scientus to conduct additional internal and external research and development. With this facility, Scientus is also a final stage applicant under Health Canada’s ACMPR licensing.

Please contact Scientus directly to learn more about our company and its sphere of operations.

Scientus Pharma Inc.
209 Dundas St. E
PO Box 31 Whiby
Whiby, Ontario
Canada L1N 5R7
info@scientuspharma.com
+1 844 493.7922